ALGS - Aligos Therapeutics Market Capitalization

Aligos Therapeutics (ALGS) maintains a patent-protected small molecule portfolio for NASH therapy that carries clinical trial risks, although skilled management from Janssen ensures strict cost control and data transparency. The market dynamics for securities with the 0.01 indicator are illustrated below. Aligos Therapeutics (ALGS) focuses on combating viral pathologies, where the treatment of chronic hepatitis B establishes a foundation for multi-year demand.

ALGS Aligos Therapeutics Inc.: Market Capitalization in the range 07/04/2022 - 11/12/2026

Comprehensive metric breakdowns and analytics for aligos.com (ALGS)

- market price and analyst price targets:

Price Chart Aligos Therapeutics, Inc.|ALGS - Price Target Chart

- market capitalization statistics:

Market Capitalization Aligos Therapeutics, Inc.|ALGS - Full Takeover Company Value

- issuer book value statistics:

Net Assets per Single Share Aligos Therapeutics|ALGS - Book Valuation of Business|Market Value to Book Value Ratio aligos.com|ALGS - Total Asset Value of Company

- debt and liquidity details:

Total Debt to Capital Aligos Therapeutics|ALGS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Aligos Therapeutics, Inc.|ALGS - Company Aggregate Debts|Debt to Book Capitalization Ratio Aligos Therapeutics, Inc.|ALGS - Company Long-Term Loans and Borrowings|Company Short-Term Debt Aligos Therapeutics|Quick Ratio aligos.com

- business earnings and investment ratios data:

ALGS - Net Profit|Future Profit Aligos Therapeutics|ALGS - Company Value to Net Income|Future Price to Earnings Aligos Therapeutics, Inc.|ALGS - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Aligos Therapeutics, Inc.|ALGS - Operating income before deduction of amortization|Net earnings per share for the last 12 months Aligos Therapeutics|ALGS - Earnings per share for the last twelve months|Quarterly EPS earnings growth aligos.com|ALGS - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Aligos Therapeutics

Fundamental company analysis:ALGS (Aligos)

The assessment of Aligos Therapeutics (ALGS) financial stability begins with an analysis of its total equity value. This metric measures the market value of the entire business, reflecting market confidence in its assets. The market capitalization trend demonstrates capital adaptability to the results of developing multimodal hepatitis B treatments. Narrowing volatility here signals a stabilization of investor expectations. The final trend determines the viability of the innovative strategy for combating liver diseases.

Key competitors